MarketBeat on MSN1h
Wall Street's Most Wanted: 2 Highly Shorted Stocks Right Now
Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling ...
ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update
Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...
Novo Nordisk A/S (NVO): Among the Stocks That Will Go to The Moon According to Analysts
We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...
Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs
Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.